One Medical Buys Iora Health
The primary care clinic operator One Medical (NASDAQ: ONEM) has expanded its network size with the acquisition of Boston, Massachusetts-based Iora Health. Under the terms of the agreement, Iora Health shareholders will receive 56.1 million shares of One Medical stock valued at the company’s closing price of $35.59 on June 4, 2021, or approximately $2.1 billion in total deal value. Iora Health shareholders are expected to own approximately 26.75% of the combined company. Iora Health is a national network of primary care clinics offering holistic, personalized care to patients through online and in-person sessions with individual health coaches. The company provides services such as... Read More »
P3 Health Partners Goes Public
The private equity-backed P3 Health Partners is going public in a multi-billion-dollar merger with a SPAC. P3 Health Partners is merging with Foresight Acquisition Corp. (NASDAQ: FORE), and the combined company will have an estimated post-transaction enterprise value of $2.3 billion with an estimated equity value of $2.4 billion from the contribution of at least $180 million in cash proceeds from the transaction. P3 Health Partners was a portfolio company of Chicago Pacific Founders, which is exiting its investment in the company. P3 Health Partners is a patient-centered and physician-led population health management company that supports providers, physicians and practices as they... Read More »
Charles River Laboratories Buys Vigene Biosciences
The global contract research organization Charles River Laboratories International, Inc. (NYSE: CRL) is back with a new deal for Vigene Biosciences, Inc. The deal is valued at $292.5 million in cash up front, plus contingent additional payments of up to $57.5 million based on future performance. Vigene Biosciences is a gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The acquisition of Vigene Biosciences will enhance Charles River’s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector. Vigene is expected to generate annual revenue of $30 to $35... Read More »
Thermo Fisher Bets $20 Billion on Leading CRO
The laboratory and diagnostics giant Thermo Fisher Scientific Inc. (NYSE: TMO) announced a huge deal for an international contract research organization (CRO) last week. Thermo Fisher is buying PPD, Inc. (NASDAQ: PPD), a leading CRO providing broad, integrated drug development, laboratory and lifecycle management services. Its customers include pharmaceutical, biotechnology, medical device, academic and government organizations. The company has offices in 47 countries and more than 26,000 employees. Its headquarters is based in Wilmington, North Carolina. Thermo Fisher is offering $17.4 billion for PPD, or $47.50 per share for the company, a premium of approximately... Read More »
The MOB Market Heats Up
The market for medical office buildings (MOB) showed plenty of activity in 2020, and that doesn’t seem to be slowing down in 2021. According to search results in our Healthcare Deals Database, there have been 18 transactions announced since January 1, driven primarily by announcements from Montecito Medical Real Estate, which reported nine of those deals. Montecito Medical, one of the largest privately-held companies specializing in healthcare-related real estate, added nearly 350,000 square feet in property across eight states. One of the most notable purchases was for a three-story, 91,300 square-foot facility in Sandusky, Ohio. The property is 100% leased to Northern Ohio Medical... Read More »